WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2018/04/19

WuXi AppTec Expands Site in the United States for Drug Development Testing Services

SHANGHAI and CRANBURY,NJ, April 19, 2018 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey. The grand opening event was honored by the presence of state and local officials including State Senator Linda Greenstein. The new facility will enhance WuXi’s integrated testing service portfolio enabling drug developers to accelerate their projects from labs to patients.

Read more

2018/02/22

WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

Shanghai, February 22, 2018 - STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announce they have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.

Read more

2017/10/18

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

SHANGHAI, China & AUSTIN, Texas, Oct. 18, 2017 - WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has acquired ResearchPoint Global (RPG), a US-based contract research organization (CRO) with expertise spanning across all major therapeutic areas.

Read more

2017/10/09

WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

SHANGHAI, Oct. 9, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award.

Read more

2017/07/31

WuXi’s Pharmaceutical Development Services Division Merges with STA

Shanghai, July 31, 2017: STA Pharmaceutical Co., Ltd. (STA) – a WuXi AppTec company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – announces that it has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.

Read more